We are incredibly excited to be able to bring our community together with Dr Geoff McCowage for this very special webinar to talk about the upcoming TiNT MEK Inhibitor Research Trial.
Dr Geoff McCowage is a senior paediatric oncologist at the Children's Hospital Westmead, is CEO of Australasian Children’s Cancer Trials and is the lead clinician for the first Australian-led clinical trial of the MEK Inhibitor drug, Trametinib.
The five-year study will investigate the effectiveness of Trametinib for the treatment of plexiform neurofibromas and optic pathway gliomas. In addition to monitoring the expected reduction in tumour size, it will also monitor the improvement in pain, function, and quality of life, as well as brain function and social development.
WHO SHOULD JOIN THE WEBINAR?
This is a FREE event hosted by the Children's Tumour Foundation and is open to anyone.
We recommend that anyone who is living with NF1 or caring for someone with NF1 should join the webinar to understand whether they or their child/children are eligible.
The team are also looking for volunteer patients with NF1 who DON’T need treatment with Trametinib, and will be explained during the session.
WHAT TO EXPECT
This a unique opportunity to hear directly from the person who is responsible for ensuring this trial is made available to Australian and New Zealand patients and will cover the following topics:
- What is a MEK inhibitor
- How do MEK inhibitors work in NF
- Prior research into MEK Inhibitors
- Timing and eligibility criteria for the Australian TiNT clinical Trial
Date: Wed 2 December 2020
Time: 12pm AEDT for 1 hour